Short time administration of antirheumatic drugs - Methotrexate as a strong inhibitor of osteoblast's proliferation in vitro

Head and Face Medicine

Volumn 8, Issue 1, 2012, Pages

  Annussek, Tobias ^a   Kleinheinz, Johannes ^a   Thomas, Szuwart ^a   Joos, Ulrich ^a   Wermker, Kai ^a  

^a UNIVERSITY HOSPITAL MÜNSTER   (Germany)

Author keywords

Antirheumatic drugs; Bone metabolism; In vitro; Methotrexate; Osteoblast

Indexed keywords

ANTIRHEUMATIC AGENT; METHOTREXATE; OSTEOCALCIN;

ANIMAL; ARTICLE; BONE REMODELING; CATTLE; CELL CULTURE; CELL DIVISION; CELL PROLIFERATION; COMPARATIVE STUDY; CYTOLOGY; DOSE RESPONSE; DRUG ADMINISTRATION; DRUG EFFECT; HUMAN; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; METABOLISM; OSTEOBLAST; PATHOPHYSIOLOGY; REFERENCE VALUE; RHEUMATOID ARTHRITIS; RISK ASSESSMENT;

ANIMALS; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; BONE REMODELING; CATTLE; CELL DIVISION; CELL PROLIFERATION; CELLS, CULTURED; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; HUMANS; IMMUNOHISTOCHEMISTRY; METHOTREXATE; OSTEOBLASTS; OSTEOCALCIN; REFERENCE VALUES; RISK ASSESSMENT;

EID: 84866645186     PISSN: None     EISSN: 1746160X     Source Type: Journal    
DOI: 10.1186/1746-160X-8-26     Document Type: Article

References (23)

1. Aletaha D, et al. 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/ European League Against Rheumatism collaborative initiative. Arthritis Rheum 2010, 62(9):2569-2581. 10.1002/art.27584, 20872595.
2. Alamanos Y, Voulgari PV, Drosos AA. Incidence and Prevalence of Rheumatoid Arthritis, Based on the 1987 American College of Rheumatology Criteria: A Systematic Review. Semin Arthritis Rheum 2006, 36(3):182-188. 10.1016/j.semarthrit.2006.08.006, 17045630.
3. Alamanos Y, Drosos AA. Epidemiology of adult rheumatoid arthritis. Autoimmun Rev 2005, 4(3):130-136. 10.1016/j.autrev.2004.09.002, 15823498.
4. McInnes IB, Schett G. The pathogenesis of rheumatoid arthritis. N Engl J Med 2011, 365(23):2205-2219. 10.1056/NEJMra1004965, 22150039.
5. Colmegna I, Ohata BR, Menard HA. Current understanding of rheumatoid arthritis therapy. Clin Pharmacol Ther 2012, 91(4):607-620. 10.1038/clpt.2011.325, 22357455.
6. Scott DL, Wolfe F, Huizinga TW. Rheumatoid arthritis. Lancet 2010, 376(9746):1094-1108. 10.1016/S0140-6736(10)60826-4, 20870100.
7. Detert J, Pischon N, Burmester GR, Buttgereit F. Pathogenesis of parodontitis in rheumatic diseases. Z Rheumatol 2010, 69(2):109-112. 10.1007/s00393-009-0560-1, 20107818.
8. Singh JA, et al. 2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care Res (Hoboken) 2012, 64(5):625-639.
9. O'Dell JR. Therapeutic strategies for rheumatoid arthritis. N Engl J Me 2004, 350(25):2591-2602.
10. Benedek TG. Methotrexate: from its introduction to non-oncologic therapeutics to anti-TNF-α. Clin Exp Rheumatol 2010, 28(5 Suppl 61):3-8.
11. Braun J, Rau R. An update on methotrexate. Curr Opin Rheumatol 2009, 21(3):216-223. 10.1097/BOR.0b013e328329c79d, 19373092.
12. Tian H, Cronstein BN. Understanding the mechanisms of action of methotrexate: implications for the treatment of rheumatoid arthritis. Bull NYU Hosp Jt Dis 2007, 65(3):168-173.
13. Hider SL, Bruce IN, Thomson W. The pharmacogenetics of methotrexate. Rheumatology (Oxford) 2007, 46(10):1520-1524.
14. Gaujoux-Viala C, Smolen JS, Landewé R, et al. Current evidence for the management of rheumatoid arthritis with synthetic disease-modifying antirheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of rheumatoid arthritis. Ann Rheum Dis 2010, 69(6):1004-1009. 10.1136/ard.2009.127225, 20447954.
15. Salliot C, van der Heijde D. Long-term safety of methotrexate monotherapy in patients with rheumatoid arthritis: a systematic literature research. Ann Rheum Dis 2009, 68(7):1100-1104. 10.1136/ard.2008.093690, 2689525, 19060002.
16. Xian CJ, Cool JC, Scherer MA, Macsai CE, Fan C, Covino M, Foster BK. Cellular mechanisms for methotrexate chemotherapy-induced bone growth defects. Bone 2007, 41(5):842-850. 10.1016/j.bone.2007.07.021, 17884747.
17. Jones DB, Nolte H, Scholubbers JG, Turner E, Veltel D. Biochemical signal transduction of mechanical strain in osteoblast-like cells. Biomaterials 1991, 12:101-110. 10.1016/0142-9612(91)90186-E, 1652292.
18. Bologna C, Edno L, Anaya JM, et al. Methotrexate concentrations in synovial membrane and trabecular and cortical bone in rheumatoid arthritis patients. Arthritis Rheum 1994, 37(12):1770-1773. 10.1002/art.1780371210, 7986223.
19. Uehara R, Suzuki Y, Ichikawa Y. Methotrexate (MTX) inhibits osteoblastic differentiation in vitro: possible mechanism of MTX osteopathy. J Rheumatol 2001, 28(2):251-256.
20. Minaur NJ, Jefferiss C, Bhalla AK, Beresford JN. Methotrexate in the treatment of rheumatoid arthritis. I. In vitro effects on cells of the osteoblast lineage. Rheumatology (Oxford) 2002, 41(7):735-740.
21. Scheven BA, van der Veen MJ, Damen CA, et al. Effects of methotrexate on human osteoblasts in vitro: modulation by 1,25-dihydroxyvitamin D3. J Bone Miner Res 1995, 10(6):874-880.
22. Meyer U, Büchter A, Wiesmann HP, Joos U, Jones DB. Basic reactions of osteoblasts on structured material surfaces. Eur Cell Mater 2005, 9:39-49.
23. Heldmann F, Braun J. Perioperative use of methotrexate. Clin Exp Rheumatol 2010, 28(5 Suppl 61):110-113.